Multiple Sclerosis | Market Forecast update.
'Growing market will almost reach the $20bn mark'
By Daniel Chancellor, Lead Analyst
15 August 2013
I am a Lead Analyst covering the CNS and rare disease markets at Datamonitor Healthcare. I joined in early 2010, having ...
Read full bio
Datamonitor Healthcare uses a company-reported, sales-based approach to estimate drug sales for multiple sclerosis in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) from 2012 to 2021.
Datamonitor Healthcare values the multiple sclerosis market at $12.0bn in the US, Japan, and five major EU markets. A strong growth trajectory, aided by new product launches, is expected to continue until 2018, by which time the market will peak at $18.3bn.
Injectable treatments, valued at $10.6bn in 2012, will increasingly be eschewed in favor of novel oral treatments such as Tecfidera, Gilenya, and Aubagio, on account of their superior efficacy and/or tolerability profiles, as well as improved convenience. By 2021, sales of oral multiple sclerosis therapies will total $7.6bn.
Tecfidera will become the dominant multiple sclerosis therapy as Biogen Idec translates its successes in the clinic into blockbuster revenues in the marketplace. Datamonitor Healthcare projects peak-year sales of $4.5bn over the 2012–21 period.
Historical company-reported sales data and pricing information in the US, Japan, and five major EU markets are collated to generate a sales volume of the multiple sclerosis market over 2009–12. These calculated volume and pricing data are trended over 2012–21, incorporating future event assumptions, to create Datamonitor Healthcare’s company-reported, sales-based forecast.
This is a Multiple Sclerosis analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.
- For more information on this research, please contact
- For current clients, please log-in to view the full analysis at: